- Molecular NameCarisoprodol
- SynonymCarisoprodate; Carisoprodatum; Isomeprobamate; Isoprotane; Isoprothane
- Weight260.334
- Drugbank_IDDB00395
- ACS_NO78-44-4
- Show 2D model
- LogP (experiment)1.498
- LogP (predicted, AB/LogP v2.0)2.5
- pkaN/A
- LogD (pH=7, predicted)2.5
- Solubility (experiment)0.3 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.32
- LogSw (predicted, AB/LogsW2.0)0.65
- Sw (mg/ml) (predicted, ACD/Labs)1.24
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds9
- TPSA90.65
- StatusFDA approved
- AdministrationN/A
- PharmacologyA centrally-acting skeletal muscle relaxant.
- Absorption_valueN/A
- Absorption (description)Absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding58.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP2C19-mediated). It is metabolised principally to meprobamate, which is active, and to hydroxymeprobamate and their glucuronide conjugates.
- Half life0.9~2.4 h
- ExcretionLess than 1% of a dose is excreted in the urine as unchanged drug in 24 h and about 5% is excreted as meprobamate in the same period. It is distributed in substantial amounts into breast milk.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives
- LD50 (rat)LD50=4.61 (mice)
- LD50 (mouse)N/A